Natco Pharma Ltd.

NATCOPHARM

Market Cap
₹17,883 Cr.
P/E
14.00

Natco Pharma Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics
Other Income
Other Income is not affecting ratios of the company
Depreciation Effect
Company is depreciating a lower percentage of assets. This is contributing to an increase in Net Profit
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Chances of aggressive revenue recognition - Operating profit of company is not getting converted to cash and recievables rising faster than sales
Capex vs ROCE
ROCE of the company has increased over the last three years
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been selling the stock which is usually a good time to buy
Share price
Share price has increased over last 10 years due to earnings
ROE
ROE has decreased vs 10 year trend
Working Capital
Company has significant working capital which is dragging its ROCE and ROE
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a discount to 3 year historic valuations
ROE
Latest
14.68%
3yr Average
9.79%
5yr Average
12.01%
Net Profit Margin
Latest
26.42%
3yr Average
18.88%
5yr Average
22.3%
ROCE
Latest
17.62%
3yr Average
12.17%
5yr Average
15.05%
Debt to Equity
Latest
0.03
3yr Average
0.06
5yr Average
0.08
Market Share
0.07% (as of Jul 22)
Anti - Diabetes - Market Share
0.74% (as of Jul 22)
Anti-Infectives - Market Share
16.71% (as of Nov 21)
Antineo Plastic - Market Share
0.11% (as of Nov 21)
Blood Related - Market Share
0.56% (as of Jul 22)
Cardiovascular - Market Share
30% (as of Mar 19)
Copaxone - Market Share
locked Source
0% (as of Jul 22)
Gastro-Intestinal - Market Share
0.01% (as of Jul 21)
Neurological - Market Share
0.38% (as of Nov 21)
Pain - Market Share
0.47% (as of Jul 22)
Pharmaceutical Sector - Market Share
0.30% (as of May 21)
Respiratory - Market Share
34.62% (as of May 19)
Urology - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Segment Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Formulation

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Break-Up -Formulation

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • US DMF Filings (.)
      Source
    • Number of ANDA's Filed in USA (.)
      Source
    • Number of ANDA's Approved By USFDA (.)
      Source
    • Domestic Sales Growth - YoY (%)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Brands
    Afinitor
    Aubagio
    Imbruvica
    Kyprolis
    Nexavar
    Pomalyst
    Revlimid
    Sovaldi
    Tarceva
    Tykerb
    Zytiga
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Natco Pharma Ltd.
    Natco Pharma: Business Model Simplified - JST Investments
    Chasing Optionalities - SOIC
    View the discussion on ValuePickr
    Natco Pharma: Chasing Optionalities - Ankush Agrawal
    Interview with Mr Rajeev Nannapaneni, Vice Chairman & CEO at Natco Pharma - Moneylife
    Business Analysis Of Natco Pharma - Value Educator
    NatcoPharma - Complex generics focused manufacturer - Value Educator
    Natco Pharma: Imminent Growth Cycle (?) - ValuePickr
    A Deep Dive Into Natco Pharma - Numbers and Narratives
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline